Background: Carfilzomib improves the prognosis of multiple myeloma (MM) patients but significantly increases cardiovascular toxicity. The timing and effect of Carfilzomib therapy on the left ventricul
Adolescent and young adult patients aged 15 to 39 years with a diagnosis of sarcoma who were scheduled to receive high-dose Dox (≥300 mg/m²) at a single tertiary cancer center between 2018 and 2022 we
The BC_cardiotox database is a result of the collaboration between the University of A Coruña and the University Hospital of A Coruña. It contains information about 531 breast cancer patients and aims
We present the case of a 64-year-old female with stage IV gastric adenocarcinoma, pulmonary and abdominal wall metastases, and no history of cardiovascular disease. In palliative care, she received sy
